We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen: Anemia Drug Should Not Be Used for Off-Label Cancer Treatment
Amgen: Anemia Drug Should Not Be Used for Off-Label Cancer Treatment
January 29, 2007
Amgen’s anemia drug Aranesp should not be used to treat fatigue or to reduce the need for red blood cell transfusions in cancer patients because it is ineffective and potentially dangerous for these uses, the company said.